Copyright © 2002 by the European Society of Cardiology.
Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis
a Department of Internal Medicine, University Hospital of Groningen, Groningen, The Netherlands
b Department of Rheumatology, University Hospital of Groningen, Groningen, The Netherlands
revised August 20, 2001; accepted August 22, 2001
Abstract
Aims Patients with AA and AL amyloidosis have a limited life-expectancy. The aim of this study was to investigate whether heart rate variability can predict mortality in these patients.
Methods and Results Twenty-two recently diagnosed patients with AA and 23 patients with AL amyloidosis were included. Fifteen patients (5AA, 10AL) died within 1 year. Twenty-four hour Holter recording was performed to quantify the mean of all normal to normal RR-intervals (mean NN) and the standard deviation of all normal to normal RR-intervals (SDNN). The SDNN predicted 1-year mortality in the total group of patients with amyloidosis. The median SDNN was 73ms. In patients with an SDNN
73ms, the risk of dying within 1 year was found to have increased 3·5-fold (P=0·0036; 95%CI 1·111·0). An SDNN
50ms, a predictor of mortality in other patient groups, increased the risk of dying within 1 year 22-fold (P=0·0001; 95%CI 5·490·4). In contrast to patients with AA amyloidosis, in the subgroup analysis of patients with AL amyloidosis the SDNN remained a predictive parameter (SDNN
50ms: risk ratio 11·5, 95%CI 2·456·2, P=0·0025).
Conclusion The SDNN is a strong predictor of short-term mortality in patients with AL amyloidosis.
Key Words: Autonomic nervous system, heart rate variability, amyloidosis
f1 Correspondence: A. K. L. Reyners, University Hospital of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
References
- Dubrey SW, Cha K, Anderson J. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141157
[Abstract/Free Full Text] - Kyle RA, Gertz MA, Greipp PR. A trial of three regimens for primary amyloidosis: colchicine, alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med. 1997;336:12021207
[Abstract/Free Full Text] - Sezer O, Eucker J, Jakob C, Possinger K. Diagnosis and treatment of AL amyloidosis. Clin Nephrol. 2000;53:417423[ISI][Medline]
- Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol. 1994;8:627634[CrossRef][ISI][Medline]
- Joss N, Mclaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000;93:535542
[Abstract/Free Full Text] - Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine. 1991;70:246256[Medline]
- Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 1021 year follow-up of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20:20512057[ISI][Medline]
- Wallis MS, Stough DB IV. Extended survival of patients with primary systemic amyloidosis. Cutis. 1992;49:143
- Kyle RA, Gertz MA, Greipp PR. Long-term survival (10 years and more) in 30 patients with primary (AL) amyloidosis. Kyle RA, Gertz MA. Amyloid and amyloidosis 1998. New York: Parthenon Publishing Group; 1999. p. 151153
- Cueto-Garcia L, Reeder GS, Kyle RA. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737743[Abstract]
- Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992;13:623627
[Abstract/Free Full Text] - Berg AM, Anderson JJ, Chipkin SR. Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival. Amyloid. 1994;1:3946
- Reyners AKL, Hazenberg BPC, Haagsma EB, Tio RA, Reitsma WD, Smit AJ. The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid. 1998;5:193199[ISI][Medline]
- Husby G. Immunoglobulin-related (AL) amyloidosis. Clin Exp Rheumatol. 1983;1:353358[ISI][Medline]
- Circulation. 1996;93:10431065
[Free Full Text] - La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998;351:478484[CrossRef][ISI][Medline]
- Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256262[CrossRef][ISI][Medline]
- Lombardi F, Mortara A. Heart rate variability and cardiac failure. Heart. 1998;80:213214
[Free Full Text] - Tsuji H, Venditti FJ, Manders ES. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90:878883
[Abstract/Free Full Text] - Malik M, Camm AJ, Janse MJ, Julian DG, Frangin GA, Schwartz PJ. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol. 2000;35:12631275
[Abstract/Free Full Text] - Dekker JM, Crow RS, Folsom AR. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC study. Circulation. 2000;102:12391244
[Abstract/Free Full Text]
This article has been cited by other articles:
![]() |
J. B. Selvanayagam, P. N. Hawkins, B. Paul, S. G. Myerson, and S. Neubauer Evaluation and Management of the Cardiac Amyloidosis J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2101 - 2110. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Kholova and H W M Niessen Amyloid in the cardiovascular system: a review J. Clin. Pathol., February 1, 2005; 58(2): 125 - 133. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

